Mycosynthetix, Inc.

Biotech · Acquired

Small molecule therapeutics targeting pathogenic free-living amoebae infections

Grants
$341K
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
1
1 granted · 0 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Agriculture · Production Of The Organic Herbicide Mevalocidin By Fungi$100,000
Federal grantDepartment of Health and Human Services · Phase I · Fungal Metabolites Fuel Drug Discovery for Pathogenic Free-Living Amoebae$241,400
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1384CHESAPEAKE GENOMIC SYSTEMS, LLC——
1385STRESS THERAPEUTICS, INC.——
1386Atrapos Therapeutics, LLC——
1387Mycosynthetix, Inc.——
1388SELSYM BIOTECH INC——
1389NAWGEN, LLC——
1390VIVREON BIOSCIENCES LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 1 granted of 1

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.